{"id":"NCT04546425","sponsor":"Pfizer","briefTitle":"20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants","officialTitle":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE GIVEN AS A SERIES OF 2 INFANT DOSES AND 1 TODDLER DOSE IN HEALTHY INFANTS","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-09-09","primaryCompletion":"2022-04-22","completion":"2023-02-18","firstPosted":"2020-09-14","resultsPosted":"2023-05-15","lastUpdate":"2024-01-08"},"enrollment":1258,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Pneumococcal Disease"],"interventions":[{"type":"BIOLOGICAL","name":"20-valent pneumococcal conjugate vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"13-valent pneumococcal conjugate vaccine","otherNames":[]}],"arms":[{"label":"20-valent pneumococcal conjugate vaccine","type":"EXPERIMENTAL"},{"label":"13-valent pneumococcal conjugate vaccine","type":"ACTIVE_COMPARATOR"}],"summary":"20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants","primaryOutcome":{"measure":"Percentage of Participants With Local Reactions Within 7 Days After Dose 1: Primary Study Population","timeFrame":"Within 7 days after Dose 1","effectByArm":[{"arm":"20vPnC: Primary Study Population","deltaMin":20.7,"sd":17.6},{"arm":"13vPnC: Primary Study Population","deltaMin":22.7,"sd":19.4}],"pValues":[]},"eligibility":{"minAge":"42 Days","sex":"ALL","healthyVolunteers":true,"inclusionCount":2,"exclusionCount":4},"locations":{"siteCount":66,"countries":["Australia","Belgium","Czechia","Denmark","Estonia","Finland","Italy","Netherlands","Norway","Poland","Russia","Slovakia"]},"refs":{"pmids":["38456705"],"seeAlso":["https://pmiform.com/clinical-trial-info-request?StudyID=B7471012"]},"adverseEventsSummary":{"seriousAny":{"events":34,"n":601},"commonTop":["Irritability (IRRITABILITY)","Hypersomnia (INCREASED SLEEP)","Injection site pain (PAIN)","Decreased appetite (DECREASED APPETITE)","Injection site erythema (REDNESS)"]}}